AIM - AIM ImmunoTech gains on research deal for lead asset

• AIM ImmunoTech ( NYSE: AIM ) jumped ~17% in the morning hours Tuesday after announcing a collaboration with Erasmus University Medical Center and AstraZeneca ( AZN ) for an investigator-initiated study for its lead asset Ampligen (rintatolimod).
• According to the agreement, Erasmus MC will run the study to evaluate rintatolimod in combination with AstraZeneca’s ( AZN ) immune checkpoint inhibitor durvalumab in patients with metastatic pancreatic ductal adenocarcinoma.
• AIM ImmunoTech ( AIM ) and AstraZeneca ( AZN ) are expected to provide their respective study drugs for the trial.
• The company said that Ampligen has previously indicated pre-clinical synergistic effects with checkpoint inhibitors improving survival rates and efficacy in animal tumors.
• In November, AIM ImmunoTech ( AIM ) shares surged after the company announced the FDA orphan drug designation for Ampligen to treat Ebola.

For further details see: